Biotech RadarJobs updated

COMPANY

Kymera Therapeutics, Inc.

HQ: Watertown, MA source · kymeratx.com ↗ · New England

Clinical Phase 2

22 open jobs · last seen Oct 23, 2026 · 15 sources

Keywords: oncology breast cancer other solid tumors Atopic Dermatitis Hidradenitis Suppurativa Asthma (Diagnosis) Eosinophilic Asthma Non Hodgkin Lymphoma Peripheral T-cell Lymphoma Cutaneous T-Cell Lymphoma Large Granular Lymphocytic Leukemia T-cell Prolymphocytic Leukemia Myeloid Malignancies Acute Lymphocytic Leukemia Lymphomas Diffuse Large B Cell Lymphoma DLBCL MYD88 Gene Mutation KT-621 KT-579 KT-333 KT-253 KT-413 KT-474

Location: Watertown, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Since the raise (Dec 11, 2025): 22 of 22 open jobs were first seen after it.

22Open jobs$943.1MRaised (2 yrs)12Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate Director or Director, Statistical ProgrammingWatertown, MAOct 9, 2026Oct 9, 2026
Clinical Trial Associate or Senior Clinical Trial AssociateWatertown, MASep 8, 2026Oct 9, 2026
Sr. Manager or Associate Director or Director, BiostatisticsWatertown, MASep 8, 2026Oct 9, 2026
Associate Director or Director, Clinical ScientistWatertown, MAAug 28, 2026Oct 9, 2026
Director or Senior Director, Regulatory CMCWatertown, MAAug 21, 2026Oct 9, 2026

See all 22 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (22 open jobs at last check). source ↗
  2. Trial start Phase 1: A Study to Evaluate Different Oral Formulations of KT-621 source ↗
  3. Trial start Phase 2: A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study source ↗
  4. Trial start Phase 1: First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants source ↗
  5. Trial start Phase 2: A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma source ↗
  6. Raise Follow-on offering: $692.3M (total, as published), announced Dec 11, 2025. Source: company release on GlobeNewswire. source ↗
  7. Trial start Phase 2: A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis source ↗
  8. Raise Follow-on offering: $250.8M (total, as published), announced Jun 26, 2025. Source: SEC filing. source ↗
  9. Trial start Phase 1: Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) source ↗
  10. Trial start Phase 1: First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants source ↗
  11. Trial start Phase 1: Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors source ↗
  12. Trial start Phase 1: Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL source ↗
  13. Trial start Phase 1: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors source ↗
  14. Trial start Phase 1: A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) source ↗
  15. Trial start —: Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 22

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate Director or Director, Statistical ProgrammingWatertown, MAOct 9, 2026Oct 9, 2026Senior
Clinical Trial Associate or Senior Clinical Trial AssociateWatertown, MASep 8, 2026Oct 9, 2026Mid
Sr. Manager or Associate Director or Director, BiostatisticsWatertown, MASep 8, 2026Oct 9, 2026Senior
Associate Director or Director, Clinical ScientistWatertown, MAAug 28, 2026Oct 9, 2026Senior
Director or Senior Director, Regulatory CMCWatertown, MAAug 21, 2026Oct 9, 2026Senior
Director or Senior Director, Program ManagementWatertown, MAAug 21, 2026Oct 9, 2026Senior
Director or Senior Director, CMC Program ManagementWatertown, MAAug 19, 2026Oct 9, 2026Senior
Associate Director, Analytical DevelopmentWatertown, MAAug 19, 2026Oct 9, 2026Senior
Associate Director, New Product StrategyWatertown, MAAug 14, 2026Oct 9, 2026Senior
Senior Director, Outcomes, Value & AccessWatertown, MAAug 13, 2026Oct 9, 2026Senior
Manager or Sr. Manager, Clinical Trial Feasibility LeadWatertown, MAAug 11, 2026Oct 9, 2026Mid
Associate Director or Director, PBPK & Biopharmaceutics ModelingWatertown, MAAug 11, 2026Oct 9, 2026Senior
IT Director, Development Business PartnerWatertown, MAAug 4, 2026Oct 9, 2026Senior
Director or Senior Director, Business DevelopmentWatertown, MAJul 29, 2026Oct 9, 2026Senior
Senior Director, Early Phase Formulation DevelopmentWatertown, MAJul 24, 2026Oct 9, 2026Senior
Senior or Executive Director, AI Strategy & ApplicationsWatertown, MAJul 21, 2026Oct 9, 2026Executive
Associate Director, Clinical OperationsWatertown, MAJul 9, 2026Oct 9, 2026Senior
Director or Senior Director, Regulatory AffairsWatertown, MAJun 25, 2026Oct 9, 2026Senior
Senior Scientist or Principal Scientist, Targeted ProteomicsWatertown, MAMay 26, 2026Oct 9, 2026Senior
Vice President, Pharmaceutical DevelopmentWatertown, MAMay 26, 2026Oct 9, 2026Executive
Sr. Clinical Trial ManagerWatertown, MAMay 6, 2026Oct 9, 2026Mid
Senior Manager or Associate Director, Strategic SourcingWatertown, MAApr 15, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $943.1M. Last 2 years.

Clinical trials (lead sponsor) 12

RecordTitlePhaseStatusStartPrimary completion
NCT07677059A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma StudyPhase 2RecruitingJun 25, 20262028-12 (estimated)
NCT07323654A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaPhase 2RecruitingJan 28, 20262027-12 (estimated)
NCT07217015A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisPhase 2Active, not recruitingNov 24, 20252027-06 (estimated)
NCT07823205A Study to Evaluate Different Oral Formulations of KT-621Phase 1Recruiting2026-102027-04 (estimated)
NCT07412288First-in-human Study of Orally Administered KT-579 in Healthy Adult ParticipantsPhase 1RecruitingFeb 23, 20262026-12 (estimated)
NCT06945458Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)Phase 1CompletedApr 17, 2025Nov 10, 2025 (actual)
NCT06673667First-in-human Study of Orally Administered KT-621 in Healthy Adult ParticipantsPhase 1CompletedOct 22, 2024Apr 23, 2025 (actual)
NCT05225584Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsPhase 1CompletedMay 19, 2022Mar 3, 2025 (actual)
NCT05775406Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid TumorsPhase 1CompletedMay 15, 2023Dec 18, 2024 (actual)
NCT05233033Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLPhase 1CompletedJun 13, 2022Jul 28, 2023 (actual)
NCT04772885A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)Phase 1CompletedFeb 23, 2021Oct 20, 2022 (actual)
NCT04440410Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic DermatitisNot listedCompletedMay 28, 2020Mar 24, 2021 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Kymera Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback